Trident Texofab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was INR 721.16 million compared to INR 597.88 million a year ago. Revenue was INR 731.27 million compared to INR 601.83 million a year ago. Net income was INR 21.62 million compared to INR 3.16 million a year ago. Basic earnings per share from continuing operations was INR 2.15 compared to INR 0.31 a year ago. Diluted earnings per share from continuing operations was INR 2.15 compared to INR 0.31 a year ago.